CHAPEL HILL, N.C, Oct. 12, 2017 /PRNewswire/ -- TARGET
PharmaSolutions, Inc., a real-world clinical data company, is
pleased to announce that Bristol-Myers Squibb (BMY) has extended
its strategic partnership for TARGET-NASH to a multi-year agreement.
Bristol-Myers Squibb is committed to the discovery and development
of medicines for fibrosis, including NASH.
TARGET-NASH is a longitudinal
observational study that evaluates patients with nonalcoholic fatty
liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). TARGET-NASH is collecting retrospective and
prospective data on its enrolled patients and is developing a
biorepository which its stakeholders can access for translational
studies (including those of genomics and biomarkers). To
date, TARGET-NASH has enrolled
over 2,364 patients at 55 sites. There have been multiple
presentations on TARGET-NASH at
leading academic conferences and a methodology publication is
currently in press. TARGET-NASH
will enroll up to 15,000 patients over the coming years.
TARGET-NASH is led by an academic
steering committee chaired by Drs. Arun
Sanyal, MD (Virginia Commonwealth
University); Ken Cusi, MD
(University of Florida), and Brent
Tetri (St. Louis University).
Meg Powell, CEO of TARGET
PharmaSolutions, stated "We are pleased to extend our partnership
with Bristol-Myers Squibb for TARGET-NASH. We believe this is a testament to the
long-term value the TARGET model generates for our industry
partners throughout the development and commercialization process,
including benefits for Research, Clinical, Regulatory, Medical
Affairs, Commercialization, Marketing, Health Economics and
Outcomes groups."
TARGET PharmaSolutions provides insights and actions to improve
clinical, medical, and commercial outcomes throughout the
pharmaceutical development and commercialization process. The
TARGET model organizes a community of stakeholders, including
pharmaceutical manufacturers, key opinion leaders, regulatory
agencies, and patient advocacy groups, around a specific disease to
generate real world evidence about the natural history of the given
disease, current treatment paradigm, and patient outcomes.
This model enables TARGET's stakeholders to answer critical
strategic and planning questions and to fulfill regulatory and
payer requests. The TARGET model also provides access to a
biorepository linked to validated clinical outcomes, including
patient reported outcomes (PROs).
TARGET PharmaSolutions was formed in February, 2015 and has four
disease communities: TARGET-NASH
(nonalcoholic steatohepatitis), TARGET-PBC (primary biliary
cholangitis), TARGET-HCC (hepatocellular carcinoma), and TARGET-IBD
(inflammatory bowel disease). The TARGET model is based on the
success of HCV-TARGET, a case study in Hepatitis C. Formed in 2011
by Drs. Michael Fried, MD
(University of North Carolina) and
David Nelson, MD (University of Florida), HCV-TARGET has enrolled
over 11,000 patients and has generated data that has been used by
physicians, payers, and regulatory agencies around the world.
About TARGET PharmaSolutions
TARGET PharmaSolutions is a privately held real-world clinical
data company that provides pharmaceutical and biotechnology
partners a more efficient way to generate data that can be used to
better understand the natural history of diseases, current
treatment paradigms, and patient outcomes in the real-world
setting. TARGET PharmaSolutions is based in Chapel Hill, N.C. For more information,
visit www.targetpharmasolutions.com.
View original
content:http://www.prnewswire.com/news-releases/bristol-myers-squibb-bmy-extends-strategic-partnership-with-target-pharmasolutions-for-target-nash-300535524.html
SOURCE TARGET PharmaSolutions, Inc.